Xeris Pharmaceuticals | XERS - Debt


Xeris Pharmaceuticals reported $257.65M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Celltrion KRW 171.09B 2.05T Jun/2025
Cspc Pharmaceutical CNY 495M 12.33M Jun/2025
Dianthus Therapeutics USD 1.28M 45K Sep/2025
Divis Laboratories Ltd INR 40M 40M Mar/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Kangmei Pharma CNY 131.64M 90.18M Jun/2025
Knight Therapeutics CAD 106.24M 1.5M Sep/2025
Laboratorios Farma EUR 129.3M 14.89M Jun/2025
Malin Corporation EUR 100K 0 Dec/2023
Medical Developments International AUD 1.99M 152K Jun/2025
Neuren Pharmaceuticals AUD 0 0 Dec/2024
Pacira USD 376.72M 203.77M Sep/2025
Perrigo USD 3.65B 454.7M Jun/2025
Pharma Mar EUR 51.4M 405K Jun/2025
Qiagen NV USD 2.13B 683.16M Sep/2025
Sartorius EUR 4.66B 25.7M Jun/2025
Sino Biopharmaceutical CNY 9.71B 33.98M Dec/2024
Supernus Pharmaceuticals USD 31.77M 531K Jun/2025
Tilray USD 640.95M 35.17M Jun/2022
Zz Pientze Pharmaceu CNY 1.07B 52.69M Jun/2025